Amyloidosis Drug Improves Outcomes, Survival

MedPage Today) — LONDON — Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III trial.
And the benefits…